Lv1
44 积分 2023-08-10 加入
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
17天前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
18天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
18天前
已完结
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
20天前
已完结
Changing frontline AML treatment patterns from 2013 to 2022
20天前
已完结
Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis
25天前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
25天前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
26天前
已关闭
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis. Expert Rev Anticancer Ther. 2026 Aug;26(8):1051-1060
27天前
已完结
Cancer burden and control in China: landscape, trends and challenges
30天前
已完结
皖公网安备34019202002308
